口服避孕藥市場：按產品類型、配方、劑量、品牌和分銷管道分類的全球市場預測，2026-2032年

預計到 2025 年，口服避孕藥市場價值將達到 196.6 億美元，到 2026 年將成長至 210.5 億美元，到 2032 年將達到 317.7 億美元，複合年成長率為 7.09%。

主要市場統計數據
基準年 2025	196.6億美元
預計年份：2026年	210.5億美元
預測年份 2032	317.7億美元
複合年成長率 (%)	7.09%

對現代口服避孕藥市場進行簡要概述，重點關注影響相關人員決策的臨床、監管和准入趨勢。

口服避孕藥仍然是全球生殖健康策略的基石，其在計劃生育、臨床護理和公共衛生政策中的作用也在不斷演變。醫療服務提供者、保險公司和生產商所處的環境受到監管重點變化、遠端醫療的擴展以及患者對安全性、便利性和成本透明度的期望不斷提高的影響。因此，對於那些必須在臨床療效與供應鏈和商業性現實之間取得平衡的利害關係人相關人員，了解影響處方行為、依從性和可及性的趨勢至關重要。

數位醫療的擴張、監管調整和製劑的演變如何重塑口服避孕藥市場的取得途徑、處方行為和供應商策略。

口服避孕藥市場正經歷著變革性的轉變，產品研發、處方、分銷和使用者認知正在改變。數位醫療的進步加速了遠端醫療諮詢和線上藥局配藥的發展，加快了處方箋取得速度，但也帶來了合規性和檢驗的新挑戰。同時，一些地區正在推動非處方藥（OTC）的普及，而另一些地區則在擴大藥劑師的處方權。這些因素正在改變傳統的准入把關安全隔離網閘，並促使生產者重新思考包裝、標籤和病患支援服務。

本分析探討了美國近期採取的關稅措施如何促使整個口服避孕藥生態系統進行供應鏈重組、來源多元化和籌資策略調整。

美國近期實施的貿易政策措施對口服避孕藥供應鏈的各個環節都產生了累積影響。進口關稅的提高和對上游供應商監管力度的加強，正在改變活性成分和生產配方成本的計算方式，促使製造商重新評估籌資策略、製造地和庫存政策。因此，企業擴大探索近岸外包、雙重採購和長期供應商契約，以降低關稅波動帶來的風險並確保供應的連續性。

將產品類型、配方細節、給藥策略、品牌定位和分銷管道與競爭和營運重點聯繫起來的詳細細分分析。

關鍵的市場細分洞察揭示了產品特性、配方設計、給藥策略、品牌定位和分銷管道結構如何相互作用，從而決定競爭機會和風險。基於產品類型，複方口服避孕藥和黃體素單藥療法之間的市場差異導致了處方模式、耐受性特徵和目標患者群體特徵的差異，進而影響行銷、醫學教育和處方集。基於配方，雙相、單相和三相製劑的差異會影響出血模式、週期管理預期以及醫護人員和病患教育所需的訊息。

美洲、歐洲、中東和非洲以及亞太地區的區域戰略考量決定了監管重點、通路和製造選擇。

區域趨勢為不同地理叢集的相關人員帶來了不同的策略挑戰。在美洲，法律規範、支付方人口結構和遠端醫療普及率影響著零售藥局、醫院採購和線上分銷之間的平衡，從而塑造了特定的市場進入模式和報銷考量。相較之下，歐洲、中東和非洲地區的監管要求和醫療保健基礎設施存在顯著差異，因此需要採取適應性強的許可策略、差異化的臨床證據包以及客製化化的經銷夥伴，以反映當地的採購慣例和公共部門的採購週期。

配方創新、供應彈性、策略夥伴關係和生命週期管理的競爭資訊決定了口服避孕藥領域的領導地位。

口服避孕藥領域的企業競爭格局取決於配方創新、供應鏈韌性、商業性可行性以及向臨床醫生和支付方展現差異化價值的能力。關鍵策略舉措包括投資以患者為中心的訊息傳遞和用藥依從性支援服務，確保關鍵中間體的長期供應契約，以及優先選擇監管途徑以加速市場准入。此外，生命週期管理策略，例如分階段配方變更、包裝重新設計和擴大適應症，也被廣泛用於提升產品相關性並維持處方醫生的支持。

為行業領導者制定可操作的策略重點，以整合證據產生、採購韌性、數位化參與和相關人員，從而確保永續的市場優勢。

產業領導者應採取多管齊下的策略，協調臨床證據的取得、供應鏈的柔軟性以及管道特定的商業化，以保持競爭優勢。首先，將可靠的真實世界依從性研究和上市後監測整合到產品系列中，可以增強與支付方的議價能力，並有助於制定臨床訊息。其次，透過合格的雙重採購和選擇性近岸外包，實現原料藥（API）和成品生產的多元化，可以在保持成本競爭力的同時，降低貿易政策波動和物流中斷帶來的風險。

嚴謹的混合方法研究框架，結合相關人員訪談、監管和臨床文獻整合以及交叉檢驗的情境分析，為可操作的結論提供了支持。

本分析所依據的研究結合了定性和定量方法，檢驗趨勢、整合不同觀點，並為決策者提供切實可行的建議。主要研究包括對臨床醫生、採購負責人、藥房經理和行業高管進行結構化訪談，以獲取有關處方行為、籌資策略和分銷挑戰的第一手資料。次要研究則利用監管文件、臨床指引更新、政策公告和公開文獻，來分析藥物取得和偏好方面的變化。

總結指出，監管變革、供應韌性、配方創新和以患者為中心的交付是該領域未來成功的核心驅動力。

總而言之，口服避孕藥市場格局正處於轉折點，監管政策的轉變、數位化管道的拓展以及供應鏈趨勢的交織，正在重塑產品的研發、交付和使用方式。積極將臨床證據的生成與靈活的籌資策略和管道專屬的商業化相結合的相關人員，將更有能力滿足不斷變化的患者需求並降低風險。過渡性政策措施和貿易趨勢凸顯了靈活採購和建立長期供應商關係的重要性，而製劑差異化和病患支援服務則為企業建立競爭優勢提供了清晰的路徑。

目錄

第1章：序言

第2章：調查方法

• 調查設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查的前提
• 研究限制

第3章執行摘要

• 首席體驗長觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 產業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 上市策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會映射
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 口服避孕藥市場：依產品類型分類

• 複方口服避孕藥
• 黃體素單藥治療

第9章 口服避孕藥市場：以劑型分類

• 雙相
• 單相型
• 三相型

第10章 口服避孕藥市場：依劑量分類

• 高劑量
• 低劑量

第11章 口服避孕藥市場：依品牌分類

• 品牌商品
• 非專利的

第12章 口服避孕藥市場：依通路分類

• 醫院藥房
  • 私立醫院
  • 公立醫院
• 線上平台
• 零售藥房

第13章 口服避孕藥市場：依地區分類

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第14章 口服避孕藥市場：依組別分類

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第15章 口服避孕藥市場：依國家分類

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第16章：美國：口服避孕藥市場

第17章 中國：口服避孕藥市場

第18章 競爭格局

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• AbbVie Inc.
• Amneal Pharmaceuticals LLC
• Aurobindo Pharma Limited
• Bayer AG
• Cipla Ltd
• Dr. Reddy's Laboratories Ltd
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Ltd
• HLL Lifecare Limited
• Johnson & Johnson Services, Inc.
• Lupin Pharmaceuticals Inc.
• Mankind Pharma Ltd
• Mayne Pharma Group Ltd
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd
• Zydus Lifesciences Ltd

The Oral Contraceptive Pills Market was valued at USD 19.66 billion in 2025 and is projected to grow to USD 21.05 billion in 2026, with a CAGR of 7.09%, reaching USD 31.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 19.66 billion
Estimated Year [2026]	USD 21.05 billion
Forecast Year [2032]	USD 31.77 billion
CAGR (%)	7.09%

A succinct orienting overview of the contemporary oral contraceptive pills landscape highlighting clinical, regulatory, and access dynamics shaping stakeholder decisions

Oral contraceptive pills remain a cornerstone of reproductive health strategies globally, and their role in family planning, clinical care, and public health policy continues to evolve. Providers, payers, and manufacturers operate in an environment shaped by shifting regulatory priorities, expanding telehealth provision, and changing patient expectations for safety, convenience, and cost transparency. Consequently, understanding the dynamics that influence prescribing practices, adherence, and accessibility is essential for stakeholders who must balance clinical efficacy with supply chain and commercial realities.

In addition, the social and political context surrounding contraception influences demand patterns, formulary decisions, and public sector procurement strategies. Emerging digital health pathways are reshaping how patients access prescriptions and adhere to recommended regimens, while formulation innovation and lifecycle management of both branded and generic products are redefining competitive dynamics. Therefore, an actionable introduction to this landscape must acknowledge the interplay between clinical guidance, regulatory frameworks, and market channels, and set the stage for deeper analysis that follows in subsequent sections.

How digital health expansion, regulatory rebalancing, and formulation evolution are reshaping access, prescribing behavior, and supplier strategies in the oral contraceptive market

The oral contraceptive market is experiencing transformative shifts that are altering how products are developed, prescribed, distributed, and perceived by users. Advances in digital health have accelerated telemedicine consultations and online pharmacy fulfillment, enabling more rapid access to prescriptions while also introducing new compliance and verification challenges. At the same time, policy movements toward over-the-counter availability in some jurisdictions and expanded pharmacist prescribing authority in others are changing the traditional gatekeepers of access and prompting manufacturers to reconsider packaging, labeling, and patient support services.

Moreover, clinical and formulation trends are prompting differentiated product strategies. Patient-centric formulations and lower-hormone options are gaining attention as providers seek to balance efficacy with tolerability, and there is renewed focus on real-world adherence data to inform guideline updates and payer decisions. Parallel to these clinical shifts are supply-side transformations: contract manufacturing optimization, API sourcing diversification, and vertical integration strategies are being deployed to mitigate disruptions. Finally, increased competition from generic manufacturers and a heightened emphasis on value-based procurement are driving innovation in patient support programs, digital adherence tools, and evidence generation to sustain brand differentiation.

Analyzing how recent United States tariff measures are prompting supply chain realignment, sourcing diversification, and procurement strategy adjustments across the oral contraceptive ecosystem

Recent trade policy measures introduced in the United States have created a cumulative impact across multiple facets of the oral contraceptive supply chain. Increased import tariffs and heightened scrutiny of upstream suppliers can alter the cost calculus for active pharmaceutical ingredient procurement and finished-dose manufacturing, prompting manufacturers to reevaluate sourcing strategies, manufacturing footprints, and inventory policies. As a result, companies are increasingly considering nearshoring, dual-sourcing, and long-term supplier contracts to reduce exposure to tariff volatility and ensure continuity of supply.

At the clinical procurement level, hospitals, clinics, and pharmacies are responding to these shifts by reassessing purchasing agreements and inventory buffers. Transitional effects include renegotiation of tender terms and closer collaboration between procurement and regulatory affairs teams to anticipate customs clearance complexities. In response to potential cost pressures, some manufacturers are enhancing operational efficiency through process improvements and scale consolidation, while others pursue strategic partnerships to secure critical intermediates. Importantly, these structural adjustments are unfolding alongside policy and judicial reviews that may change the long-term tariff landscape, so stakeholders should plan for both immediate operational contingencies and sustained strategic realignments.

In-depth segmentation intelligence linking product type, formulation nuances, dosage strategies, brand positioning, and distribution channels to competitive and operational priorities

Key segmentation insights reveal how product characteristics, formulation design, dosing strategies, brand positioning, and channel structures interact to determine competitive opportunity and risk. Based on Product Type, the market distinctions between combined oral contraceptives and progestin-only pills drive differences in prescribing patterns, tolerability profiles, and target patient cohorts, which in turn influence marketing, medical education, and formulary approaches. Based on Formulation, the differences among biphasic, monophasic, and triphasic designs affect bleeding patterns, cycle control expectations, and the messaging required for clinician and patient education.

Furthermore, based on Dosage Strength, the strategic differentiation between high dose and low dose pills has implications for adverse event profiles, adherence considerations, and patient preference segmentation. Based on Brand, the tension between branded and generic offerings shapes lifecycle management, reimbursement strategies, and investment in patient support or real-world evidence generation. Finally, based on Distribution Channel, the structure that encompasses hospital pharmacy, online platforms, and retail pharmacy-with the hospital pharmacy further studied across private hospital and public hospital environments-determines procurement models, reimbursement flows, inventory practices, and the configuration of patient access programs. Integrating these segmentation lenses enables more precise commercial planning, tailored messaging for clinicians and patients, and alignment of manufacturing volumes with channel-led demand.

Regional strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory priorities, distribution pathways, and manufacturing choices

Regional dynamics create distinct strategic imperatives for stakeholders operating across different geographic clusters. In the Americas, regulatory frameworks, payer mixes, and telehealth adoption rates influence the balance between retail pharmacy, hospital procurement, and online distribution, driving specific go-to-market models and reimbursement considerations. In contrast, the Europe, Middle East & Africa grouping exhibits wide heterogeneity in regulatory requirements and healthcare infrastructure, which necessitates adaptive licensing strategies, differentiated clinical evidence packages, and tailored distribution partnerships that reflect local procurement norms and public-sector procurement cycles.

Meanwhile, the Asia-Pacific region presents a diverse set of market conditions where rapid digital adoption intersects with variable regulatory timelines and manufacturing capabilities. In many jurisdictions within this region, strong local manufacturing ecosystems and evolving intellectual property enforcement standards affect decisions about local production versus export orientation. Taken together, these regional variations require companies to deploy nuanced market-entry strategies, prioritize regulatory and commercial investments by country or cluster, and synchronize supply chain and distribution models with regional payer and provider behaviors.

Competitive intelligence revealing how formulation innovation, supply resilience, strategic partnerships, and lifecycle management define leadership in the oral contraceptive category

Competitive dynamics among companies active in the oral contraceptive category are defined by a combination of innovation in formulations, supply chain resilience, commercial execution, and the ability to demonstrate differentiated value to clinicians and payers. Leading strategic approaches include investing in patient-centric information and adherence services, securing long-term supply agreements for key intermediates, and prioritizing regulatory pathways that accelerate market access. In addition, lifecycle management tactics such as incremental formulation changes, packaging redesigns, and expanded indications are commonly used to extend product relevance and maintain prescriber loyalty.

Partnerships and alliances, including those with contract manufacturers, digital health platforms, and specialty distributors, are increasingly central to delivering end-to-end solutions that address both clinical adherence and convenience. Meanwhile, companies focusing on generic entry leverage scale manufacturing and cost optimization to compete on price, while larger innovators may emphasize clinical evidence, patient support infrastructure, and brand trust to preserve premium positioning. Across these strategies, firms that align R&D priorities with real-world outcomes and that coordinate effectively across regulatory, supply chain, and commercial functions are better positioned to navigate evolving policy and distribution landscapes.

Actionable strategic priorities for industry leaders to synchronize evidence generation, sourcing resilience, digital engagement, and stakeholder advocacy for sustained market advantage

Industry leaders should adopt a multi-dimensional strategy that harmonizes clinical evidence generation, supply chain flexibility, and channel-specific commercialization to sustain competitive advantage. First, integrating robust real-world adherence studies and post-marketing surveillance into product portfolios will strengthen payer negotiations and inform clinical messaging. Second, diversifying API and finished-dose manufacturing through qualified dual sourcing and selective nearshoring will reduce exposure to trade policy shifts and logistical disruptions while maintaining cost competitiveness.

Moreover, companies should accelerate their digital engagement strategies by embedding telehealth-compatible prescribing support, personalized adherence tools, and seamless e-commerce fulfillment to meet growing patient expectations. Concurrently, active engagement with policymakers, payers, and professional societies will help shape favorable prescribing frameworks and pharmacist scope-of-practice expansions. Finally, leaders should consider targeted investments in brand-differentiating services such as nurse-led counseling, patient education platforms, and value-based contracting pilots to demonstrate outcomes and foster long-term trust with prescribers and patients.

A rigorous mixed-methods research framework combining stakeholder interviews, regulatory and clinical literature synthesis, and cross-validated scenario analysis to underpin actionable conclusions

The research underpinning this analysis relies on a combination of qualitative and quantitative approaches designed to validate trends, triangulate perspectives, and identify practical implications for decision makers. Primary research included structured interviews with clinicians, procurement officers, pharmacy directors, and industry executives to capture firsthand insights on prescribing behaviors, procurement strategies, and distribution challenges. Secondary research drew on regulatory filings, clinical guideline updates, policy announcements, and open-source literature to contextualize shifts in access and formulation preferences.

Data synthesis employed a cross-validation framework that reconciled stakeholder interviews with documented regulatory changes and supply chain developments, while scenario analysis was used to explore the implications of policy and trade variations. Limitations of the methodology include the inherent lag between policy announcements and observable market responses, and the variability of clinical and procurement practices across jurisdictions. Nonetheless, the combined methodological approach provides a robust foundation for strategic recommendations, and the findings were further reviewed by domain experts to ensure relevance and practical applicability.

Concluding synthesis that connects regulatory change, supply resilience, formulation innovation, and patient-centric delivery as the core drivers of future success in the category

In summary, the oral contraceptive landscape is at an inflection point where regulatory shifts, digital access pathways, and supply chain dynamics converge to reshape how products are developed, delivered, and used. Stakeholders who proactively align clinical evidence generation with adaptive sourcing strategies and channel-specific commercialization will be better equipped to meet evolving patient needs and mitigate risk. Transitional policy measures and trade developments underscore the importance of agile procurement and long-term supplier relationships, while formulation differentiation and patient support services offer clear avenues for competitive advantage.

Looking ahead, sustained success will depend on the ability to integrate cross-functional insights into coherent strategies that address both near-term operational challenges and longer-term clinical and market trends. By prioritizing resilience, evidence, and patient-centric delivery models, organizations can navigate uncertainty and harness emerging opportunities to improve access and outcomes for patients who rely on oral contraceptive pills.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Contraceptive Pills Market, by Product Type

• 8.1. Combined Oral Contraceptives
• 8.2. Progestin-Only Pills

9. Oral Contraceptive Pills Market, by Formulation

• 9.1. Biphasic
• 9.2. Monophasic
• 9.3. Triphasic

10. Oral Contraceptive Pills Market, by Dosage Strength

• 10.1. High Dose
• 10.2. Low Dose

11. Oral Contraceptive Pills Market, by Brand

• 11.1. Branded
• 11.2. Generic

12. Oral Contraceptive Pills Market, by Distribution Channel

• 12.1. Hospital Pharmacy
  • 12.1.1. Private Hospital
  • 12.1.2. Public Hospital
• 12.2. Online Platforms
• 12.3. Retail Pharmacy

13. Oral Contraceptive Pills Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Oral Contraceptive Pills Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Oral Contraceptive Pills Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Oral Contraceptive Pills Market

17. China Oral Contraceptive Pills Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. AbbVie Inc.
• 18.6. Amneal Pharmaceuticals LLC
• 18.7. Aurobindo Pharma Limited
• 18.8. Bayer AG
• 18.9. Cipla Ltd
• 18.10. Dr. Reddy's Laboratories Ltd
• 18.11. GlaxoSmithKline plc
• 18.12. Glenmark Pharmaceuticals Ltd
• 18.13. HLL Lifecare Limited
• 18.14. Johnson & Johnson Services, Inc.
• 18.15. Lupin Pharmaceuticals Inc.
• 18.16. Mankind Pharma Ltd
• 18.17. Mayne Pharma Group Ltd
• 18.18. Merck & Co., Inc.
• 18.19. Novartis AG
• 18.20. Pfizer Inc.
• 18.21. Sanofi S.A.
• 18.22. Sun Pharmaceutical Industries Ltd
• 18.23. Teva Pharmaceutical Industries Ltd
• 18.24. Zydus Lifesciences Ltd

LIST OF FIGURES

• FIGURE 1. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 13. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 51. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 52. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 53. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 54. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 55. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 56. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 57. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 58. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 59. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 60. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 61. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 62. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 63. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 64. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 65. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 66. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 67. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 68. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 69. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 70. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 71. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 72. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 73. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 74. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 75. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 76. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 79. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 80. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 81. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 82. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 83. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 84. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 85. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 86. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 87. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 88. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 89. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 90. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 91. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 92. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 93. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 94. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 95. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 96. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 97. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 98. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 99. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 100. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 101. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 102. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 103. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 104. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 105. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 106. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 107. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 108. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 109. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 110. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 111. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 112. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 113. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 114. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 115. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 116. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 117. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 118. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 119. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 120. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 121. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 122. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 123. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 124. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 125. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 126. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 127. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 128. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 129. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 130. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 131. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 132. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 133. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 134. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 135. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 136. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 137. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 138. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 139. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 140. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 141. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 142. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 143. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 144. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 145. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 146. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 147. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 148. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 149. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 150. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 151. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 152. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 153. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 154. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 155. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 156. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 157. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
• TABLE 158. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 159. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
• TABLE 160. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
• TABLE 161. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
• TABLE 162. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
• TABLE 163. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 164. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)